Previous studies have shown that PBK is highly trans-activated in various cancers including ovarian cancer (Ma et al., 2022), lymphoma (Wang et al., 2022), kidney cancer (Sun et al., 2022), and colon cancer (Koshino et al., 2022), which is a promising molecular target for cancer-targeted therapy. This evidence concerns the gene PBK and colonic neoplasm.